Related Experiment Video
Updated: Jan 23, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment
Jinsy A Andrews1, Lucie I Bruijn2, Jeremy M Shefner2
1From the Eleanor and Lou Gehrig ALS Center (J.A.A.), Columbia University, New York, NY; ALS Association (L.I.B.), Washington, DC; and Department of Neurology (J.M.S.), Barrow Neurological Institute, University of Arizona College of Medicine, Phoenix. Dr. Bruijn is currently at Bruijn-Yard Neuroscience R&D Consultant. Ja2289@cumc.columbia.edu.
The US Food and Drug Administration (FDA) issued draft guidance for amyotrophic lateral sclerosis (ALS) drug development, incorporating community input to improve clinical trial efficiency and accelerate new treatments.
Area of Science:
- Neurology
- Drug Development
- Clinical Research
Background:
- The US Food and Drug Administration (FDA) released draft guidance for amyotrophic lateral sclerosis (ALS) drug development in February 2018.
- This guidance incorporated extensive input from the ALS community, including researchers, industry, advocacy groups, patients, and caregivers.
Purpose of the Study:
- To analyze the alignment between the FDA's draft guidance, community recommendations, and revised ALS Clinical Trial Guidelines.
- To identify opportunities for enhancing the efficiency of drug development in ALS.
Main Methods:
- Comparative analysis of three key documents: FDA draft guidance, ALS community recommendations, and updated ALS Clinical Trial Guidelines.
- Discussion of areas of agreement and divergence among the documents.
Main Results:
- Identified areas of consensus and opportunities for improving ALS drug development efficiency.
- Highlighted the need for further research in biomarkers, efficacy endpoints, and predictive algorithms.
Conclusions:
- Greater alignment among stakeholders can be achieved through continued research and patient engagement.
- Incorporating patient experience data throughout the drug development process is crucial for facilitating the approval of new ALS treatments.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Trial and Error and Algorithm
Guidelines for Nursing Documentation II
Timely documentation is crucial to ensure continuity of care for patients. Any delays in recording or reporting medical information can result in medical errors and even adverse patient outcomes. From medication administration to diagnostic test results, every detail must be accurately and promptly documented to provide the best possible care for patients.
Legal Guidelines for Documentation
Guidelines for Sketching a Curve

